Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Lobo, Jennifer Mason ^a   Dicker, Adam P ^b   Buerki, Christine ^c   Daviconi, Elai ^c   Karnes, R Jeffrey ^d   Jenkins, Robert B ^d   Patel, Nirav ^a   Den, Robert B ^b   Showalter, Timothy N ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c GenomeDx Biosciences Inc   (Canada)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; ASSAY; CANCER GROWTH; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DECISION TREE; GENOMIC CLASSIFIER TEST; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SURVIVAL PREDICTION; AGED; COHORT ANALYSIS; DECISION SUPPORT SYSTEM; GENETICS; GENOMICS; PATHOLOGY; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

AGED; COHORT STUDIES; DECISION SUPPORT TECHNIQUES; GENOMICS; HUMANS; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; PRECISION MEDICINE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS;

EID: 84926611269     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116866     Document Type: Article

References (42)

1. Garraway LA, Verweij J, Ballman KV (2013) Precision oncology: an overview. J Clin Oncol 31:1803-1805. doi: 10.1200/JCO.2013.49.4799 PMID: 23589545
2. Garraway LA (2013) Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol 31:1806-1814. doi: 10.1200/JCO.2012.46.8934 PMID: 23589557
3. Simonds NI, Khoury MJ, Schully SD, Armstrong K, Cohn WF, et al. (2013) Comparative effectiveness research in cancer genomics and precision medicine: currents landscape and future prospects J Natl Cancer Inst 105:929-936. doi: 10.1093/jnci/djt108 PMID: 23661804
4. Goddard KAB, Knaus WA, Whitlock E, Lyman GH, Feigelson HS, et al. (2012) Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genet Med 14:633-642. PMID: 22516979
5. Thompson IM Jr., Tangen CM, Paradelo J, Lucia MS, Miller G, et al. (2006) Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296:2329-2335. PMID: 17105795
6. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Troyer D, et al. (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181:956-962. doi: 10.1016/j.juro.2008.11.032 PMID: 19167731
7. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, et al. (2005) Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366:572-578. PMID: 16099293
8. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, et al. (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 27:2924-2930. doi: 10.1200/JCO.2008.18.9563 PMID: 19433689
9. Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, et al. (2012) Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 380:2018-2027. doi: 10.1016/S0140-6736 (12) 61253-7 PMID: 23084481
10. Ghia AJ, Shrieve DC, Tward JD (2010) Adjuvant radiotherapy use and patterns of care analysis for marginpositive prostate adenocarcinoma with extracapsular extension: Postprostatectomy adjuvant radiotherapy: A SEER analysis. Urology 76:1169-1174. doi: 10.1016/j.urology.2010.04.047 PMID: 20709371
11. Hoffman KE, Nguyen PL, Chen MH, Chen RC, Choueiri TK, et al. (2011) Recommendations for postprostatectomy radiation therapy in the United States before and after the presentation of randomized trial. J Urol 185:116-120. doi: 10.1016/j.juro.2010.08.086 PMID: 21074194
12. Nielsen ME, Trock BJ, Walsh PC (2010) Salvage or adjuvant radiation therapy: counseling patients on the benefits. J Natl Compr Canc Network 8:228-237. PMID: 20141679
13. Showalter TN, Ohri N, Teti KG, Foley KA, Keith SW, et al. (2011 May 21) Physician beliefs and practices for adjuvant and salvage radiation therapy after prostatectomy. Int J Radiat Oncol Biol Phys [Epub ahead of print].
14. Crawford ED, Ventii K, Shore ND (2014) New biomarkers in prostate cancer. ONCOLOGY 28:1-2.
15. Badani K, Thompson DJS, Buerki C, Davicioni E, Garrison J, et al. (2013) Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. Oncotarget 4:600-609. PMID: 23592338
16. Basu A, Meltzer D (2007) Value of information on preference heterogeneity and individualized care. Med Decis Making 27:112-127. PMID: 17409362
17. Karnes RJ, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C, et al. (2013) Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol 190:2047-2053. doi: 10.1016/j.juro.2013.06.017 PMID: 23770138
18. Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, et al. (2013) Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One 8:e66855. doi: 10.1371/journal.pone.0066855 PMID: 23826159
19. Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13:322-328. PMID: 8246705
20. Barlow WE, Ichikawa L, Rosner D, Izumi S (1999) Analysis of case-cohort designs. J Clin Epidemiol 52:1165-1172. PMID: 10580779
21. Den RB, Feng FY, Showalter TN, Mishra MV, Trabulsi EJ, et al. (2014) Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int J Radiat Oncol Biol Phys 89:1038-1046. doi: 10.1016/j.ijrobp. 2014.04.052 PMID: 25035207
22. Elliott SP, Wilt TJ, Kuntz KM (2011) Projecting the clinical benefits of adjuvant radiotherapy versus observation and selective salvage radiotherapy after radical prostatectomy: a decision analysis. Prostate Cancer Prostatic Dis 14:270-277. doi: 10.1038/pcan. 2011.27 PMID: 21691281
23. Murphy SL, Xu J, Kochanek KD (2013) Death: Final Data for 2010. National Vital Statistics Reports 61:1-118. PMID: 24968617
24. Stewart ST, Lenert L, Bhatnagar V, Kaplan RM (2005) Utilities for prostate cancer health states in men aged 60 and older. Med Care 43:347-355. PMID: 15778638
25. Weinstein MC, Torrance G, McGuire A (2009) QALYs: The Basic. Value Health 12:S5-S9. doi: 10. 1111/j.1524-4733.2009.00515.x PMID: 19250132
26. Hornberger J, Lyman GH, Chien R, Meropol NJ (2012) A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs. Value Health 15:1014-1021. doi: 10.1016/j.jval.2012.07.012 PMID: 23244802
27. Blohmer JU, Rezai M, Kummel S, Kuhn T, Warm M, et al. (2013) Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting. J Med Econ 16:30-40. doi: 10.3111/13696998.2012.722572 PMID: 22966753
28. Hall PS, McCabe C, Stein RC, Cameron D (2012) Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. J Natl Cancer Inst 104:56-66. doi: 10. 1093/jnci/djr484 PMID: 22138097
29. Basu A (2009) Individualization at the heart of comparative effectiveness research: the time for i-CER has come. Med Decis Making 29:NP9-11. doi: 10.1177/0272989X09351586 PMID: 19959807
30. Cowen ME, Miles BJ, Cahill DF, Giesler RB, Beck JR, et al. (1998) The danger of applying group-level utilities in decision analyses of the treatment of localized prostate cancer in individual patients. Med Decis Making 18:376-380. PMID: 10372579
31. Elkin EB, Cowen ME, Cahill D, Steffel M, Kattan MW (2004) Preference assessment method affects decisionanalytic recommendations: a prostate cancer treatment example. Med Care 24:504-510.
32. Efstathiou JA (2012) Postoperative radiation for prostate cancer. Lancet 380:1974-1976. doi: 10. 1016/S0140-6736 (12) 61608-0 PMID: 23084480
33. Valicenti RK, Thompson IJ, Albertsen PC, Davis BJ, Goldenberg SL, et al. (2013) Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. Int J Radiat Oncol Biol Phys 86:822-828. doi: 10.1016/j.ijrobp. 2013.05.029 PMID: 23845839
34. Mishra MV, Champ CE, Den RB, Scher ED, Shen X, et al. (2011) Postprostatectomy radiation therapy: an evidence-based review. Future Oncol 7:1429-1440. doi: 10.2217/fon. 11.120 PMID: 22112318
35. Grossfeld GD, Stier DM, Flanders SC, Henning JM, SchonfeldW, et al. (1998) Use of second treatment following definitive local therapy for prostate cancer: data from the caPSURE database. J Urol 160:1398-1404. PMID: 9751363
36. Konety BR, Cowan JE, Carroll PR (2008) Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE. J Urol 179:1797-1803. doi: 10.1016/j.juro.2008. 01.044 PMID: 18343440
37. Konski A, Watkins-Bruner D, Feigenberg S, Hanlon AL, Kulkarni S, et al. (2006) Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk porostate cancer. Int J Radiat Oncol Biol Phys 66:408-415. PMID: 16887291
38. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, et al. (2004) Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291:1325-1332. PMID: 15026399
39. Boorjian SA, Tollefson MK, Thompson RH, Rangel LJ, Bergstralh EJ, et al. (2012) Natural history of biochemical recurrence after radical prostatectomy with adjuvant radiation therapy. J Urol 188:1761-1766. doi: 10.1016/j.juro.2012.07.037 PMID: 22998913
40. Krupski TL, Foley KA, Baser O, Long S, Macarios D, et al. (2007) Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications. J Urol 178:1423-1428. PMID: 17706711
41. Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, et al. (2010) Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA 304:2373-2380. doi: 10.1001/jama.2010.1720 PMID: 21119084
42. Schousboe JT, Taylor BC, Fink HA, Kane RL, Cummings SR, et al. (2007) Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA 298:629-637. PMID: 17684185